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T cell assays differentiate clinical and subclinical
SARS-CoV-2 infections from cross-reactive
antiviral responses
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Identification of protective T cell responses against SARS-CoV-2 requires distinguishing
people infected with SARS-CoV-2 from those with cross-reactive immunity to other cor-
onaviruses. Here we show a range of T cell assays that differentially capture immune function
to characterise SARS-CoV-2 responses. Strong ex vivo ELISpot and proliferation responses to
multiple antigens (including M, NP and ORF3) are found in 168 PCR-confirmed SARS-CoV-2
infected volunteers, but are rare in 119 uninfected volunteers. Highly exposed seronegative
healthcare workers with recent COVID-19-compatible illness show T cell response patterns
characteristic of infection. By contrast, >90% of convalescent or unexposed people show
proliferation and cellular lactate responses to spike subunits S1/S2, indicating pre-existing
cross-reactive T cell populations. The detection of T cell responses to SARS-CoV-2 is
therefore critically dependent on assay and antigen selection. Memory responses to specific
non-spike proteins provide a method to distinguish recent infection from pre-existing
immunity in exposed populations.
https://doi.org/10.1038/s41467-021-21856-3 OPEN
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NATURE COMMUNICATIONS |         (2021) 12:2055 | https://doi.org/10.1038/s41467-021-21856-3 | www.nature.com/naturecommunications 1
12
3
4
5
6
7
8
9
0
()
:,;
I
n late 2019, the new virus severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) emerged, causing the range of
clinical diseases known as COVID-191,2. While the majority of
SARS-CoV-2 infections are either asymptomatic or result in mild
disease, some individuals develop severe respiratory symptoms
which may result in hospital admission and death leading to high
global mortality3,4, especially older adults and those with
comorbidities5. Understanding the immune responses resulting
from exposure to SARS-CoV-2 and distinguishing these from the
responses made to seasonal coronaviruses, is a pre-requisite to
defining immune correlates of infection and protection against
subsequent SARS-CoV-2 disease. This in turn is centrally
important in comparing with protective vaccine-induced immu-
nity and may contribute to future public health policies including
shielding advice.
Antibody responses to SARS-CoV-2 are important but remain
complex. In a recent large-scale study of healthcare workers,
PCR-confirmed SARS-CoV-2 infection resulted in measurable
antibodies after 20 days in nearly all participants, with high
specificity6. However, there is wide variability. Other studies have
reported that antibodies may be absent early in the disease, levels
of neutralising antibodies are highly variable7, and antibody titres
wane over time8. In contrast, studies of SARS-CoV infection
indicate that T cell responses may be more durable9. A number of
studies have demonstrated the presence of T cell responses to the
virus during acute disease and in recovery. Using in silico-
predicted HLA-class I and II peptide pools, CD4+ T cell
responses to SARS-CoV-2 were demonstrated in all volunteers
who had recovered from COVID-19 and CD8+ responses were
demonstrated in 70%10. This study also found T cell reactivity to
SARS-CoV-2 epitopes in 50% of archived samples from pre-
pandemic (2015–2018) volunteers using a 24-h activation-
induced markers (AIM) assay. Additionally, a Swedish study
demonstrated a highly activated cytotoxic phenotype in acute
disease and vigorous polyfunctional T cell responses in con-
valescent patients11. Interestingly, the latter study reported T cell
responses to SARS-CoV-2 in seronegative household contacts,
which may represent either infection without seroconversion
or pre-existing cross-reactive immune memory to seasonal
coronaviruses.
The role of prior exposure to human seasonal coronaviruses
including alpha coronaviruses (HCoV-NL63 and HCoV-229E),
and beta coronaviruses (HCoV-HKU1 and HCoV-OC43) as well
as SARS-CoV and MERS-CoV, that may generate SARS-CoV-2
cross-reactive T cell immune responses, is of substantial interest.
Whilst prior exposure to the original SARS-CoV and to MERS-
CoV is rare and restricted to outbreaks, exposure to the seasonal
human coronaviruses is widespread. Population sero-surveys
have shown that detectable baseline levels of IgG against at least
one of the four known HCoV is near universal12–14, but there is
evidence that re-infection with the same virus can occur15,16. T
cell immunity to other coronaviruses is less well studied prior to
the 2020 pandemic, but a recent study from Singapore demon-
strated the presence of reactive responses to SARS-CoV-2 in
people who had recovered from the SARS-CoV epidemic 17 years
earlier, which are likely to represent cross-reactive memory9. Such
cross-reactive responses to other CoV may be protective against
SARS-CoV-2, be irrelevant, or could in theory contribute to
immunopathology. The role of pre-existing cross-reactive T cell
responses in immunity has been studied for other viruses
including influenza and flaviviruses. In one study where such
responses were fine-mapped, we observed that pre-existing cross-
reactive responses to the dengue virus were linked to disease
protection from Japanese Encephalitis, while symptomatic disease
was linked to the emergence of strain-specific T cells17.
Divergent data regarding SARS-CoV-2 T cell cross-reactivity
have emerged so far: recent studies of T cell immunity to SARS-
CoV-2 have reported levels of cross-reactive immunity to HCoV
in SARS-CoV-2 unexposed populations of up to 50%9–11,18–21
using a variety of immune assays. One such study from our
centre20 did not find significant ex vivo IFN-γ ELISpot responses
to SARS-CoV-2 in uninfected, seronegative volunteers. The dif-
ferences between these results might reflect the use of different
assays employing a range of antigenic targets, peptide con-
centrations and proliferation times.
Here we set out to address two questions using a panel of T cell
assays. First, do COVID-19 patients and seronegative controls
show different levels of responsiveness in distinct assays of T cell
function? Second, can T cell responses distinguish persons pre-
viously infected by SARS-CoV-2 from those previously infected
by seasonal coronaviruses? We find—in a large cohort of people
with a range of viral exposures—that cross-reactive memory
responses to spike protein are almost universally detected using
more sensitive assays, but that increasing viral exposure leads to
an increase in magnitude and breadth of both effector and
memory responses. These data have implications for our under-
standing of T cell cross-protection and for future studies of
memory following the pandemic.
Results
Strong and broad IFN-γ ELISpot responses in convalescence.
We first examined the T cell response to SARS-CoV-2 in freshly
isolated peripheral blood mononuclear cells (PBMC) using an
ex vivo IFN-γ ELISpot assay from 168 volunteers with PCR-
confirmed SARS-CoV-2 infection, and 112 negative controls
without evidence of SARS-CoV-2 infection (Supplementary
Table 1). IgG antibody responses to spike measured by ELISA are
shown in Fig. 1a and neutralising antibodies measured by a
pseudoparticle assay are shown in Supplementary Fig. 1a. Firstly,
we evaluated the magnitude of the T cell response to SARS-CoV-
2 to assess the effector T cell response following stimulation of
PBMCs with pools of overlapping peptides spanning all SARS-
CoV-2 proteins except the non-structural ORF1 (Fig. 1b and
Supplementary Table 2). We found responses to summed pools
covering SARS-CoV-2 spike protein (12 minipools of 15-mers
overlapping by 10 peptides referred to as P1–P12) (Fig. 1b, c), and
the structural and accessory proteins (7 pools of 18-mers over-
lapping by 11 peptides covering E, M, NP, ORF3, ORF6, ORF7
and ORF8) (Fig. 1b, d). We also screened PBMCs with pools
containing predicted optimal peptides targeting MHC Class II
epitopes on the SARS-CoV-2 spike protein (CD4S), and other
viral proteins (CD4All), and predicted Class I binding peptides
split into CD8A and CD8B described in Grifoni et al.13 (Fig. 1b
and Supplementary Fig. 1c).
IFN-γ responses to spike (S) pools were seen in PBMC from
34/75 (45%) of convalescent volunteers tested (Fig. 1c) with high
and frequent responses to some individual minipools including
P2 (up to 313 SFC/106 PBMC) and P8 (up to 353 SFC/106
PBMC). We identified IFN-γ responses to the structural and
accessory proteins in 65/103 (63%) of convalescent volunteers,
with especially high-magnitude responses to the membrane (M)
and nucleocapsid (NP) proteins (Fig. 1d). Combined, there was
variation in the breadth and magnitude of SARS-CoV-2-specific
responses (Supplementary Fig. 1b), and longitudinal follow-up
studies underway will define the dynamics of the T cell response
over time. IFN-γ responses were also seen in 24/29 (83%) of
convalescent volunteers following stimulation with the four pools
of predicted epitopes. Interestingly, we found especially high-
frequency responses to the CD8A pool which comprises predicted
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epitopes predominantly from the large ORF113 highlighting the
need for further exploration of immune responses to this region
(Supplementary Fig. 1c). Correlation analysis between the IFN-γ
responses to spike peptide pools measured by ELISpot and anti-
spike IgG measured by ELISA showed a significant positive
correlation (Spearman’s R= 0.4587; P < 0.0001) (Fig. 2a).
IFN-γ responses to either M or NP correlate with total T cell
responses. There was a correlation between summed responses to
spike and non-spike structural proteins (Spearman R= 0.579, P
< 0.0001, Supplementary Fig. 1d), as well as the structural and
accessory proteins and the predicted pools, indicating that when
an individual mounted a T cell response to one part of the pro-
teome they were likely to respond to another part, and responses
declined with time from symptoms (Supplementary Fig. 1e, 1f).
IFN-γ responses to either M or NP were correlates of the global
response to spike, structural and accessory proteins (Fig. 2b, c),
indicating that an assay to measure responses to M or NP could
reflect the global effector T cell response.
We did not find a significant difference between IFN-γ ELISpot
response and either age or sex (Supplementary Fig. 1g, h), but
larger studies including older adults are needed for further
exploration.
Sensitive proliferation assays demonstrate memory responses.
As our ELISpots assays were performed on total PBMCs, dis-
crimination between distinct T cell lineages inducing the response
was not possible. Moreover, the sensitivity of the ELISpot did not
allow detection of responses in all COVID-19 recovered people.
We, therefore, used a sensitive and functional flow cytometer-
based assay capable of distinguishing the CD4+ and CD8+ T cell
responses. For this, we used a T cell proliferation assay to gain
further insights into the contribution and relative proficiency of
the CD4+ or CD8+ T cell compartments to drive a proliferative
anti-SARS-CoV-2 immune response in our convalescent HCW
cohort. We first validated our assays on a small cohort of healthy
control volunteers recruited for a hepatitis C virus (HCV) vaccine
clinical trial pre-COVID1922. We showed that HCV seronegative
control volunteers made strong proliferative responses to pools of
optimal peptides covering Influenza, EBV, CMV and Tetanus
(FEC-T) but as expected, not to peptides covering HCV NS3 or
core proteins (Supplementary Fig. 2a–e). We then evaluated the
ability of CD4+ and CD8+ T cells from the COVID-19
Fig. 1 Magnitude and breadth of SARS-CoV-2-specific immune response. a Total anti-SARS-CoV-2 spike IgG antibody titres by indirect ELISA29 in
22 seronegative controls, 24 asymptomatic and 82 mildly symptomatic healthcare workers (HCWs) with PCR-confirmed SARS-CoV-2 infection, 7
hospitalised patients with severe or critical PCR-confirmed SARS-CoV-2 infection, 9 PCR-negative inpatient controls, and 11 pre-pandemic controls. b Ex
vivo IFN-γ ELISpot showing the effector T cell responses to summed SARS-CoV-2 peptide pools spanning spike, accessory and structural proteins (E, M,
NP, ORF 3, ORF6, ORF7 and ORF8), in silico-predicted pools10 and the CEF T cell control panel in cohort groups as in a. c Ex vivo IFN-γ ELISpot showing the
magnitude and breadth of effector T cell responses in 54 individual volunteers to 12 SARS-CoV-2 spike peptide pools (numbered P1 to P12) and d M, NP
and accessory proteins ORF 3, ORF6, ORF7 and ORF8 in 73 HCWs convalescent with mildly symptomatic SARS-CoV-2 infection. X axis shows number of
days from onset of symptoms (not to scale), with blank columns representing zero response in the individual tested at that time-point. SFC/106 PBMC=
spot-forming cells per million peripheral blood mononuclear cells, with background subtracted. Plots show median with error bars indicating ± IQR.
Kruskal–Wallis one-way ANOVA, with Dunn’s multiple comparisons test, was performed. Two-tailed P-values < 0.05 are shown on plots with
Supplementary Table 3 showing full Kruskal–Wallis one-way ANOVA, with Dunn’s multiple comparisons test for b. Source data are available in the source
data file.
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convalescent HCW cohort to proliferate in response to peptide
pools spanning key proteins from SARS-CoV-2. Live lympho-
cytes were separated into CD4+ or CD8+ T cells according to
gating strategy and the frequency of proliferating cells analysed
following a 7-day stimulation (Supplementary Fig. 2a). We found
a high frequency of proliferating cells and broad targeting of
SARS-CoV-2-specific CD4+ and CD8+ T cells (Fig. 3a, b, sup-
plementary Tables 4 and 5) suggesting the establishment of a
vigorous central memory population that may shape SARS-CoV-
2 recall responses. The majority of people targeted T cell
responses to M (69/107, 64% for CD4+ and 50/107, 47% for
CD8+), NP (CD4+ 63/107, 59%; CD8+ 56/107, 52%) and ORF3
(CD4+ 26/107, 24%; CD8+ 24/107, 22%) and less frequently to
ORF6 (CD4+ 4/107, 4%; CD8+ 2/107, 2%), ORF7 (CD4+ 11/107,
10%; CD8+ 6/107, 6%) and ORF8 (CD4+ 13/91, 14%; CD8+
6/91, 7%) (Fig. 3c, d). This represents a higher sensitivity to detect
antigen-specific T cell responses than in the ex vivo ELISpot
assay. Although we observed a trend for the overall magnitude of
the proliferating CD4+ T cell response to SARS-CoV-2 peptide
pools to be higher than that of the CD8+ T cell-driven response,
this did not reach significance for the peptide pools tested with
the exception of M (P= 0.0012 by Mann–Whitney’s U test)
(Supplementary Fig. 3a). Also of note, we did not find any dif-
ference in the magnitude of responding CD4+ or CD8+ T cells in
individuals who had the asymptomatic disease (detected on HCW
screening) compared with those who presented with mild
symptoms (Supplementary Fig. 3b, c). Finally, the findings from
the proliferation assays were consistent with those generated by a
second, shorter, assay measuring soluble lactate in supernatants
obtained after only 4 days of stimulation, with SARS-CoV-2
convalescent volunteers showing strong M, NP and ORF 3-
directed responses (Fig. 3e). Taken together, in our cohort of
convalescent HCWs we show wide breadth and magnitude of T
cell responses to SARS-CoV-2 proteins including both subunits of
the spike (S1 and S2), and structural and accessory proteins.
Specific CD4+ and CD8+ responses secrete multiple cytokines.
In order to determine the quality of the T cell response within our
cohort, we used an intracellular staining (ICS) panel comprised of
the activation marker CD154, degranulation marker CD107a and
effector cytokines IFN-γ, TNF and IL-2 on freshly isolated
PBMC. This allows for the assessment of both the contribution of
CD4+ and CD8+ T cell responses as well as the pattern of
cytokine response to SARS-CoV-2. As both ex vivo ELISpot and
ICS assays measure effector memory cells, we first focused our
ICS analysis on people who were ELISpot responders (>mean +
2 SD of the background) for M and NP pools, n= 31 and 41,
respectively. Representative plots are shown in Supplementary
Fig. 4. Levels of IFN-γ, IL-2 and TNF for these individuals are
shown in Fig. 4a, c. For M pools, there was a larger CD4+ T cell
response compared to a CD8+ response in terms of both IL-2
(P < 0.0001 by Wilcoxon’s two-tailed test) and TNF (P= 0.031 by
Wilcoxon’s two-tailed test) (Fig. 4a). For NP pools, there was no
Fig. 2 Correlation between antibody and total summed ex vivo ELISpot responses. a Correlation between IgG ELISA to spike and ex vivo IFN-γ ELISpot
summed response to spike (n= 110), the correlation between ex vivo IFN-γ ELISpot response to bM protein and c NP and total summed response to spike,
E, M, N, ORF 3, ORF6, ORF7 and ORF8 (n= 50), SFC/106 PBMC= spot-forming cells per million peripheral blood mononuclear cells, with background
subtracted. The correlation was performed via Spearman’s rank correlation coefficient and comparison of two groups by two-tailed Mann–Whitney U test.
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Fig. 3 Proliferative responses in CD4+ and CD8+ T cells to key SARS-CoV-2 proteins. Plot showing raw frequency (without background subtraction) of
proliferating cells in response to peptide pool stimulation in 113 volunteers in a CD4+ and b CD8+ T cells to DMSO (media), and overlapping peptide pools
spanning S1, S2, M, NP, ORF 3, ORF6, ORF7 and ORF8. c Heatmap showing the magnitude of proliferative responses to overlapping peptide pools spanning
SARS-CoV-2 proteome in CD4+ T cells and d CD8+ T cells following background subtraction. Scales on the heatmap represent the magnitude of
proliferating cells. Only data points >1% corresponding to mean + 2× SD in DMSO only well for both CD4+ and CD8+ T cells are shown. The grey box
indicates absent data where tests were not run due to sample or peptide availability. e Cellular lactate proliferative response in convalescent mild and
asymptomatic HCWs (n= 23 asymptomatic and mild symptoms) at day 4 revealed a variable response to M, NP, ORF 3, 6, 7 and 8. Heatmaps show
background-subtracted responses. Each data point represents a single volunteer and plots show median with error bars indicating ± IQR. Where indicated,
ns not significant, * = <0.05, ** = <0.01, *** = <0.001 and **** = <0.0001 by Kruskal–Wallis one-way ANOVA, with Dunn’s multiple comparisons test for
shown in Supplementary Tables 4 and 5. Number of volunteers for a–d: asymptomatic = 23, mild = 84, severe = 4, critical = 2.
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difference in the levels of IFN-γ, IL-2 or TNF expressed by CD4+
and CD8+ T cells (Fig. 4d). This difference between M and NP
responses was not due to differences in the magnitude of the
ELISpot response as they were statistically similar (median 85 vs
95 SFC/106 PBMC, P= 0.37 by Wilcoxon’s two-tailed test).
Neither was this difference due to patients with asymptomatic
disease as there were similar numbers who were ELISpot positive
for M (n= 8) and N (n= 7).
We then examined the number of functional markers co-
expressed by these cells. After excluding individuals that did not
have sufficient cells for multiple cytokine analysis either due to
the low level of response (as median ELISpot level was <100/106
PBMC for both peptide pools) and/or the number of cells
(particularly CD8+ T cells), we did not have a sufficient number
of individuals with enough cells for CD8+ T analysis but did for
CD4+ T cells (n= 9 for M and n= 4 for NP). CD4+ T cells for
both peptide pools expressed multiple cytokines with the majority
of cells expressing one or two functional markers and up to four
markers in CD4+ T cells (Fig. 4b, d).
We then performed ICS experiments using M, NP, S1 and S2
pools on an additional 26 SARS-CoV-2 PCR-positive individuals
to compare the immune responses among these peptide pools
(Supplementary Fig. 5). M, S1, and S2 pools all trended towards
higher levels of IL-2 expression by CD4+ T cells compared to
CD8+ T cells (Supplementary Fig. 5a, e, g, P= 0.051, P= 0.055,
P= 0.016, respectively. All done by Wilcoxon’s two-tailed test).
Stimulation with M pools also resulted in significantly higher
expression of IFN-γ by CD4+ T cells (Supplementary Fig. 5a,
P= 0.044 by Wilcoxon’s two-tailed test) while NP pools trended
towards higher IFN-γ expression in CD8+ T cells
Fig. 4 ICS responses in CD4+ and CD8+ T cells for M and NP pools in ELISpot positive individuals. ICS was performed on individuals with convalescent
mild cases and a positive ELISpot for the indicated peptides. PBMC were stimulated with 2 μg/ml peptide for 6 h. Expression levels of IFN-γ, IL-2 and TNF in
CD4+ and CD8+ T cells using M pools are shown in a, n= 31. Bars represent median ± IQR. Statistics were performed using a two-tailed Wilcoxon
matched-pairs signed-rank test between each cytokine in CD4+ vs CD8+ T cells. Boolean gates were then set and cytokine expression was examined in
CD4+ T cells (n= 9) using SPICE (b). Error bars represent SEM for cytokine expression figures. Expression levels of cytokines using NP pools are shown in
c (n= 41) with polyfunctionality analysis for CD4+ T cells (d) (n= 4) as above.
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(Supplementary Fig. 5d, P= 0.066 by Wilcoxon’s two-tailed test).
We again examined cytokine expression in these patients. The
low level of responses, as these individuals were not screened
using ELISpot, prevented us from effectively examining CD8+ T
cell cytokine expression. However, there were sufficient indivi-
duals with enough responding cells to examine CD4+ T cytokine
expression for M (n= 10), NP (n= 4), S1 (n= 6) and S2 (n= 3).
The vast majority of cells expressed 1–2 functional markers (with
similar patterns), with small populations of cells expressing 3 or 4
(Supplementary Fig. 5). These results were similar to the ELISpot
positive individuals mentioned above.
Uninfected show strong proliferative responses to spike. We
studied SARS-CoV-2 seronegative controls (Fig. 1a) for whom we
also evaluated T cell responses to SARS-CoV-2 peptides using
IFN-γ ELISpot, ICS and proliferation assay. In contrast to con-
valescent HCWs, SARS-CoV-2-specific IFN-γ responses were
scarcely seen in any of the SARS-CoV-2 peptide pools as mea-
sured by ex vivo ELISpot assays in 23 seronegative healthy control
volunteers (Fig. 1b). Responsiveness to common antigens
(CEF-T) in these control volunteers indicated that there were no
inherent defects in the ability of PBMCs from these donors to
mount an antigen-driven immune response. This finding of a lack
of response to SARS-CoV-2 peptides in seronegative control
volunteers by an 18-h ex vivo IFN-γ ELISpot assay was confirmed
in 13 volunteers by an independent laboratory in Sheffield, UK
(Fig. 5a). We also evaluated cryopreserved PBMC from pre-
pandemic healthy control archives and found minimal responses
to spike, structural and accessory proteins in 19 volunteers in
Oxford (Fig. 5b) and in the predicted epitope pools10 in 48 people
in Liverpool, UK (Fig. 5c).
However, using cellular proliferation assays on 20 seronegative
volunteers, we show a high frequency of proliferating CD4+ and
CD8+ T cells responding to the S1 and S2 subunit of the spike
protein with a CD4+ T cell response detected in 17/20 (85%) and
a CD8+ T cell response in 10/20 (50%) (Fig. 6a, b). In contrast,
we observed weak or no CD4+ and CD8+ T cell proliferative
responses to the structural and accessory proteins studied (M,
NP, ORF3, ORF6, ORF7 and ORF8) (Fig. 6a, b). As the
20 seronegative participants were sampled in early 2020, we also
analysed 15 cryopreserved samples from 2008 to 2019 (pre-UK
COVID19 pandemic) to exclude the possibility of asymptomatic
and undetected prior infection. Similar to the pandemic
seronegative controls, we found no or low effector T cell
responses by ELISpot assay to any of the spike, structural or
accessory proteins (Fig. 5b), but as for the pandemic seronegative
controls we detected robust T cell responses by proliferation assay
to spike proteins S1 and S2, which was of greater breadth in the
CD4+ T cells compared to their CD8+ T cell counterparts
(Fig. 6c, d). The responses show a CD4+ skew with 15/15 showing
a CD4+ T cell response and only 8/15 showing a CD8+ T cell
response above background level. Most importantly, there was
very limited cross-reactivity to the structural and accessory
proteins as measured by the proliferation assay. As with the
convalescent HCW cohort, we also performed a cellular lactate
assay using supernatants obtained after 4 days of stimulation on 8
of these people. We confirm cross-reactive responses to spike S1
and S2 subunits, and non-existent or minimal responses in
supernatants obtained from M, NP and accessory protein-
stimulated PBMCs (Fig. 6e). We compared the magnitude of
the proliferative responses to the different SARS-COV-2 peptide
pools in seronegative controls from 2020, symptomatic and
asymptomatic SARS-COV-2 PCR+ volunteers (Fig. 6f, g). We
found no difference in the spike—S1 and S2—responses but the
higher magnitude of proliferative responses to M and NP in both
CD4+ and CD8+ T cells and ORF3 and ORF8 in CD8+ T cells
alone in people who had tested positive to SARS-COV-2 (Fig. 6f,
g). For confirmation, we also compared the magnitude of
proliferative T cell responses in SARS-COV-2 seronegative
controls from 2020 with the cryopreserved pre-pandemic
seronegative controls and found the magnitude of proliferative
cells in these two seronegative groups to be similar (Supplemen-
tary Fig. 6a, b). These results, in addition to our earlier results
from people who did not generate effector T cell responses to
spike peptides in the IFN-γ ELISpot assay (Figs. 1b and 5a, c),
demonstrate the consistent evidence of proliferative T cell
memory to spike protein in the pre-existing T cell repertoire of
people naive to SARS-CoV-2.
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The robust T cell memory responses in the control groups
to spike protein are clear in our data, and consistent with a
recent study that assessed cross-reactivity using a different
assay system21 addressing the issue of whether this reflects
prior exposure to HCoVs. To explore this further, we first
tested our cohort using serologic assays and found universally
high exposure to four circulating HCoVs, as also seen in other
studies9–11,18–21 (Supplementary Fig. 7). We next addressed
the homology between S and HCoVs at the level of 9-mer
peptides and compared this to M and NP (Supplementary
Fig. 8a) The median alignment score for each spike, NP and M
proteins was 8.5, 7.5 and 6.5, respectively, which indicates that
a c CD4+ T cells  CD8+ T cells  b CD4+ T cells  CD8+ T cells  d 
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on average SARS-CoV-2 spike protein peptides are more
conserved relative to the HCoVs than M and NP proteins
(Mann–Whitney U test P-values: S vs N < 2.2 × 10−16, S vs
M < 2.2 × 10−16). Additionally, focusing on the top 5% of most
homologous peptides (alignment score > 18.5) across the three
proteins, we observed that 61%, 20% and 19% of the peptides
were in S, NP and M proteins, respectively. Finally, since
direct cross-reactivity has been shown at the level of a key set
of 61 SARS-Cov-2-derived peptides21, we assessed to what
extent this dataset supported enhanced reactivity to these
peptides derived from S vs non-S antigens. We observed
strong skewing towards S (P < 0.0001 by two-tailed Welch’s
ANOVA), with such peptides distributed in both S1 and S2, as
seen in this study (Supplementary Fig. 8b, c). Overall, these
data suggest that S contains a pool of T cell epitopes with
evident conservation and cross-reactivity and in independent
analyses of similarly HCoV-exposed populations are asso-
ciated with common T cell reactivity to S.
T cell responses in seronegative exposed healthcare workers.
Finally, to explore the use of these T cells assays to identify people
potentially exposed to SARS-CoV-2, we recruited a group of 10
highly exposed healthcare workers working in acute medicine
who had experienced symptoms compatible with COVID-19 but
had not received PCR testing at the time of symptoms, or tested
negative, and were subsequently seronegative (Supplementary
Table 6). 3/10 of these healthcare workers showed effector T cell
responses by ELISpot assay to S1, S2, M or NP (Fig. 7a) whilst 8/8
of those tested showed M and/or NP-specific T cell responses in
the proliferation assay compatible with prior infection (Fig. 7b, c).
Analysis of the breadth of SARS-CoV-2 antigen targeted by the
responding CD4+ and CD8+ T cells shows that in the highly
exposed doctors the CD4+ and CD8+ T cell response is directed
to a broader number of structural (M and NP) and accessory
(ORFs 3, 6, 7 and 8) SARS-CoV-2 peptide pools (Fig. 7d, e). This
reached statistical significance for both CD4+ and CD8+ T cells
compared to seronegative control groups (Fig. 7d, e). Lastly, we
compared the magnitude of the T cell response to SARS-CoV-2
structural and accessory proteins in the three groups – the highly
exposed HCWs, seronegative controls from 2020 and pre-
pandemic seronegative controls (combined into one group). We
found a significantly higher magnitude of CD4+ but not CD8+
T cells proliferating in response to the M, N, ORF3, 6, 7 and 8 in
the highly exposed doctors (Fig. 7f, g).
Discussion
As the global COVID-19 pandemic continues, it is important to
define which immune responses are important for protection. In
this study, we have used distinct T cell assay platforms across the
same individuals to characterise the differences between T cell
responses associated with recent SARS-CoV-2 infection and long-
term cross-reactive memory T cell responses in unexposed
populations. The effector T cell response as measured by our 18-h
ex vivo IFN-γ ELISpot assay showed a remarkable absence of
SARS-CoV-2-specific responses in most of the healthy ser-
onegative volunteers. The ELISpot assay, therefore, represents
potential as a suitable assay platform for the identification of
recent infection with SARS-CoV-2. However, this ELISpot assay
did not detect SARS-CoV-2-specific T cell responses in all people
with recent PCR-confirmed infection, and the longevity of such
responses requires further analysis in longitudinal studies. We
already noted a significant inverse correlation with magnitude by
ELISpot assay over time in the short follow-up performed here,
and ongoing work with the current convalescent HCW cohort
will define the durability of these T cell responses induced by
SARS-CoV-2 infection.
In contrast, the same healthy people showed responses to the
S1 and S2 subunits of spike protein in a 7-day CTV proliferation
assay, confirmed by analysis of lactate production. The most
likely explanation for this is that people developed cross-reactive
memory responses to the spike protein of seasonal coronaviruses
that circulate in the UK (and to which they all exhibit serologic
responses), although cross-reactivity from other human micro-
organisms is also possible, as has been described for HIV, influ-
enza and Ebola epitopes in naive volunteers23,24. The relative
focus of such pre-existing responses on S1 and S2 is consistent
with recently-published data21 where proof-of-principle for cross-
reactivity with HCoVs was shown. It is also supported by our
informatic studies showing enrichment for peptides conserved
across such coronaviruses in S compared to M and NP antigens.
Thus although cross-reactive, pre-existing T cell responses can
occur throughout the genome, we hypothesise that the relative
conservation and also the large size of the spike may lead to an
accumulation of the consistent S-specific memory responses in
the control groups seen using our assays.
Individuals in convalescence from SARS-CoV-2 infection
showed strong and broad effector CD4+ and CD8+ T cell
responses to peptides spanning the SARS-CoV-2 genome as
previously reported, with CD4+ T cells showing a polyfunctional
response20. Unfortunately, there was an insufficient number of
individuals with sufficient cell numbers available to effectively
examine CD8+ T cell cytokine expression. ELISpot responses to
the M and NP proteins were especially frequent and high, and
each correlated with the summed response to spike, structural
and accessory peptides, indicating their suitability as antigens for
screening individuals and populations for evidence of T cell
immunity following exposure to SARS-CoV-2. Additionally,
memory responses to M and NP were frequent and strong in the
proliferation assay for people in convalescence from SARS-CoV-2
but significantly less so in the seronegative control volunteers,
further supporting the use of these antigens as markers of T cell
responsiveness more closely linked with SARS-CoV-2 exposure.
Further mapping studies could identify peptides with the highest
sensitivity and specificity for SARS-CoV-2 infection, with
potential for use in defining T cell immunity at an individual and
population level.
Fig. 6 Cross-reactive T cell response in seronegative controls from 2020 and pre-COVID19 pandemic. a Heatmaps showing CD4+ and b CD8+ T cell
proliferative responses in fresh PBMCs from healthy seronegative controls (n= 20). c heatmaps showing the magnitude of cross-reactive responses in
CD4+ and d CD8+ T cell response in cryopreserved samples obtained pre-COVID19 pandemic (n= 15). Only data points >1% corresponding to mean +
2× SD in DMSO only well for both CD4+ and CD8+ T cells are shown in heatmaps. e Heatmap measuring the lactate proliferative response in both healthy
seronegative controls at day 4 revealed a strong response to spike (all S1 and S2 values divided by 2 for ease of viewing) as well a small, variable, response
to SARS-CoV-2 peptide pools. f comparative analysis of peptide pool-specific proliferative response to SARS-CoV-2 proteins in CD4+ and g CD8+ T cells
in SARS-CoV-2 seronegative controls during COVID pandemic and PCR+ volunteers. All data plotted are background subtracted (number of volunteers:
seronegative control 2020= 20, pre-pandemic seronegative = 15). For statistical comparison, all data points have been included for all groups. Each data
point represents a single volunteer and plots show median with error bars indicating ± IQR. Comparison of two groups was done by two-tailed
Mann–Whitney U test.
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The existence of substantial T cell cross-reactivity to SARS-
CoV-2 from prior HCoV exposure has been demonstrated in
non-SARS-CoV-2 infected populations from a range of geo-
graphical locations9–11,18,19,21. Here, we demonstrate the use of
the ELISpot assay to identify SARS-CoV-2-specific responses, and
our finding of absent T cell responses in unexposed volunteers
was confirmed by similar results in our three independent
laboratories (Universities of Oxford, Liverpool and Sheffield). T
cell assays vary in their sensitivity, influenced by cell number,
incubation time, antigen choice and concentration and markers
of T cell activity measured. Our ELISpot assay does not detect the
T cell responses in unexposed populations to spike and other
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SARS-CoV-2 proteins reported elsewhere. This may be due to the
relatively low cell number used in our assay (200,000 per well) but
most likely the focus on IFN-γ release rather than detection of cell
activation markers.
Most convalescent people in the study made antibodies, as
detected by IgG ELISA and pseudoparticle neutralisation assay.
Emerging literature suggests that SARS-CoV-2 IgG titres meeting
the threshold for positivity may be relatively short-lived8,25. The
current study represents a cross-sectional ‘snapshot’ in time of
human T cell responses to SARS-CoV-2 after infection. Ongoing
follow-up studies of this cohort and surveillance26 for re-infection
aligned to the UK SIREN study27 will allow further delineation of
the time course of T cell responses in parallel with humoral
responses, and the timing of any assay must be taken into account
in defining its utility. While an association is seen between
antibody and ELISpot in the PCR-positive cohort, a disjunct
exists between the antibodies and memory responses, since strong
spike responses can be seen in the PCR-negative/unexposed and
pre-pandemic groups. We need to assess in future whether any
relationship exists between the levels of these responses and levels
of seroreactivity to HCoVs.
Our study of the large ORF1 was restricted to the use of the in
silico-predicted pool CD8A10, where a high magnitude of
responses was seen. Further work will characterise the time
course of T cell responses observed in this cohort, evaluate the
ability of our assays to correctly distinguish individuals with
confirmed SARS-CoV-2 infection from unexposed controls, and
prospectively seek to identify the relationship between measurable
T cell immunity to the SARS-CoV-2 proteome and subsequent
primary or secondary infection with SARS-CoV-2.
Overall, we have shown that assessments of T cell immunity
using different assays but with the same antigens give very dif-
ferent results. Our ELISpot measure of ex vivo IFN-γ release is
valuable in defining the potential role of T cell immunity in
recently infected donors without cross-reactivity in unexposed
people. In contrast, our proliferation assay allows dissecting out
pre-existing vs SARS-CoV-2 induced immune responses by
examining responses to different antigens. Our proliferation assay
demonstrates widespread T cell memory responses to spike in
both SARS-CoV-2 infected and unexposed people, whilst T cell
memory responses to M and NP are more characteristic of pre-
vious SARS-CoV-2 infection. These two assays, in combination
with the panel of antigens, can now allow us to address critical
questions about dissecting the role of T cells—induced by SARS-
CoV-2, and possibly HCoVs and other antigens—in immune
protection in the future.
Methods
Ethics statement. Human study protocols were approved by the research ethics
committee (REC) at Yorkshire & The Humber— Sheffield (GI Biobank Study 16/
YH/0247). The study was conducted in compliance with all relevant ethical reg-
ulations for work with human participants, and according to the principles of the
Declaration of Helsinki (2008) and the International Conference on Harmoniza-
tion (ICH) Good Clinical Practice (GCP) guidelines. Written informed consent was
obtained for all patients enrolled in the study.
Study volunteers. SARS-CoV-2 positive individuals: Healthcare workers at
Oxford University Hospitals NHS Foundation Trust who tested positive for SARS-
CoV-2 following either presentation to the hospital’s Occupational Health
Department with symptoms or having a positive PCR test on the staff screening
programme26 were asked to indicate whether they were willing to be contacted by
researchers. Individuals who agreed to be contacted received an email invitation to
participate in the study. Volunteers recruited from the staff screening programme
were classified as asymptomatic if they did not report any symptoms of COVID-19
(including fever, shortness of breath, cough, loss of taste or smell, sore throat,
coryza or diarrhoea), either prior to staff screening or in the seven days following
testing positive. In total 126 symptomatic and 33 asymptomatic people were
recruited for this study. In addition, 9 hospitalised PCR-positive patients with
WHO severe or critical COVID-19 were studied.
SARS-CoV-2 negative individuals (healthy controls): 30 healthy control
volunteers in Oxford and 13 in Sheffield with no history of COVID-19 symptoms
and no antibodies to SARS-CoV-2 spike protein detected by IgG ELISA were
recruited. In addition, archived samples from 19 healthy control volunteers in
Oxford who donated blood in the pre-pandemic period (2008–2019) were studied,
alongside 48 healthy control volunteers from the pre-pandemic period in
Liverpool. In addition, 9 hospitalised PCR-negative patients with other medical
conditions were studied.
Highly exposed seronegative individuals (highly exposed HCWs): 10 acute
medicine doctors, who worked in patient-facing services during the pandemic and
experienced symptoms compatible with COVID-19, but did not receive PCR
testing at the time of symptoms or tested negative, and were anti-spike IgG
negative two months after the pandemic peak, were recruited as highly exposed
seronegative HCW participants.
Peripheral blood mononuclear cells. Peripheral blood mononuclear cells were
isolated by density gradient centrifugation using LymphoprepTM (1.077 g/ml, Stem
Cell Technologies)28. Plasma was collected and spun at 2000 × g for 10 min to
remove platelets before freezing at −80 °C for later use. PBMC were collected and
washed twice with pre-warmed R10 media: RPMI 1640 (Sigma, St. Louis, MO,
USA) supplemented with 10% heat-inactivated FCS (Sigma), 1 mM Pen/Strep and
2mM L-Glutamine (both from Sigma). After the second centrifugation, cells were
resuspended in R10 and counted using the Guava® ViaCountTM assay on the Muse
Cell Analyzer (Luminex Cooperation). The majority of assays were performed on
freshly isolated PBMC during the first peak of the pandemic using available
resources, and it was not possible to test all samples with all antigens. Assays
performed on frozen samples are indicated in the manuscript.
Antigens. For functional assays, PBMC were stimulated with three groups of
peptide pool for SARS-CoV-2: (1) Spike: 15-mers overlapping by 10 amino acid
residues for spike (S), divided into 12 ‘minipools’ P1–P12 (Proimmune)29, and
grouped into pools S1 (P1-6) and S2 (P7-12) for some assays (2) Structural and
accessory proteins: 12-20-mer peptides overlapping by 10 amino acid residues for
membrane protein (M), nucleoprotein (NP), envelope (E) protein, open reading
frame (ORF) 3, 6, 7 and 8 (Proimmune)20 and (3) Predicted epitope pools: pre-
dicted CD4+ and CD8+ pools10 from the Sette laboratory, La Jolla Institute, CA, all
used at a final concentration of 1–2 μg/ml per peptide depending on the assay.
Lyophilised peptides were reconstituted in DMSO (Sigma).
IFN-γ ELISpot assay. The kinetics and magnitude of the cellular responses to
SARS-CoV-2 were assessed by ex vivo IFN-γ ELISpot28. Fresh PBMC were used in
all ELISpot assays unless otherwise indicated in figure legends. Briefly, 96-well
Multiscreen-I plates (Millipore, UK) were coated for 3 h with 10 μg/ml GZ-4 anti-
human IFN-γ (Mabtech, AB, Sweden) at room temperature. Fresh PBMC were
added in duplicate wells at 2 × 105 cells in 50 μl per well and stimulated with 50 μl
of SARS-CoV-2 peptide pools (2 μg/ml per peptide) as indicated in the figure
legends and controls. R10 with DMSO (final concentration 0.4%, Sigma) was used
as negative control and the following reagents were used as positive controls: CEFT
peptide pool (2 µg/ml, Proimmune) and Concanavalin A (5 µg/ml final con-
centration, Sigma). After 16–18 h at 37 °C, 5% CO2, 95% humidity, cells were
removed and secreted IFN-γ was detected by adding 1 μg/ml anti-IFN-γ biotiny-
lated mAb (7-B6-1-biotin, Mabtech) for 2–3 h, followed by 1 μg/ml streptavidin
Fig. 7 T cell response in highly exposed seronegative controls. a Ex vivo IFN-γ ELISpot responses to summed SARS-CoV-2 peptide pools spanning spike,
accessory and structural proteins (E, M, NP, ORF 3, ORF6, ORF7 and ORF8) in highly exposed HCWs working in acute medical care who experienced a
COVID-19-compatible illness without PCR testing and were subsequently seronegative. Responses are shown with background subtracted, n= 10.
b Heatmaps showing CD4+ and c CD8+ T cell proliferative responses in the same population of highly exposed HCWs. All data plotted are background
subtracted, n= 8 (cells unavailable for 2). d Breadth of responses to structural and accessory proteins from SARS-COV-2 in CD4+ and e CD8+
proliferating T cells. f Magnitude of responding CD4+ and g CD8+ T cells to structural and accessory proteins from SARS-CoV-2 (M, NP, ORF3, 6, 7, 8).
Each data point represents a single volunteer and plots show median with error bars indicating ± IQR. Comparison of two groups was done by two-tailed
Mann–Whitney U test. Study ID with † was assessed from cryopreserved samples. Proliferation assay for individuals 7 and 10 was not performed. N= 35
for combined control.
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alkaline phosphatase for 1–2 h (SP-3020, Vector Labs). The plates were developed
using BCIP/NBT substrate (Pierce) according to the manufacturer’s instructions.
ELISpot plates were scanned on an AID ELISpot Reader (v.4.0) using the following
settings: intensity min 12, size min 22, gradient min 4. Results were reported as
spot-forming units (SFU) per million PBMC. The unspecific background (mean
SFU from negative control wells) was always less than 50 SFU/106 PBMC and
subtracted from experimental readings.
Intracellular cytokine stimulation assay. PBMC resuspended in R10 were plated
at 1 × 106 live cells/well into 96-well round-bottom plates and stimulated with
SARS-CoV-2 peptide pools (2 μg/ml per peptide) as indicated in the figure legends.
Media containing DMSO (0.1%, Sigma) was used as negative control and PMA
(0.05 μg/ml) with ionomycin (0.5 μg/ml, Sigma) as a positive control. CD107a
BV421 (BD Biosciences), monensin (Biolegend) and Brefeldin A (MP Biomedicals)
were added to cultures at a final concentration of 0.04 μg/ml, 0.16 μM, and 10 μg/
ml, respectively, and cells were incubated for 6 h at 37 °C, 5% CO2, 95% humidity.
Plates were placed at 4 °C overnight and subjected to flow cytometry staining as
described below. In addition to the three cytokines, CD107a was examined as was
CD154 in CD4+ T cells.
Proliferation assay. PBMCs from freshly isolated blood samples or cryopreserved
samples (denoted with †) were twice washed with 1× PBS and stained using
CellTrace® Violet (CTV, Life Technologies) at a final concentration of 2.5 μM for
10 min at room temperature. The reaction was quenched by adding cold FBS.
CTV-labelled PBMC in RPMI containing 10% human AB serum (Sigma), 1 mM
Pen/Strep and 2mM L-Glut were plated in 48 or 96-well round-bottom plates at
500,000 and 250,000 cells, respectively, and stimulated with peptide pools from
SARS-CoV-2, FEC-T, HCV NS3 or HCV core protein (1 μg/ml per peptide). Media
containing 0.1% DMSO (Sigma) representing DMSO content in peptide pools were
used as negative control and 2 μg/ml phytohemagglutinin L (PHA-L, Sigma) as
used as a positive control. Cells were subsequently incubated at 37 °C, 5% CO2,
95% humidity for 5 days without media change or 7 days with media change on
day 4 if cultures were kept beyond 5 days. At the end of incubation, cells were
subjected to flow cytometry staining as described below. Responses above 1% were
considered true positive. To determine the breadth of antigenic response targeted
by T cells, the number of peptide pools that each volunteer responded to was
counted. To determine the magnitude of the total response to structural and
accessory proteins, the average number of cells proliferating in response to any
of the peptides M, N, ORF3, 6, 7, 8 was obtained as a function of their respective
CD4+ or CD8+ T cell population and then expressed as a percentage. The
background was then subtracted from the total response for each volunteer.
Flow cytometry staining. A MIFlowCyt file (minimum information about a flow
cytometry experiment) was created as per Section VI. 4 of ‘Guidelines for the use of
flow cytometry and cell sorting in immunological studies’30 and recommended by
the International Society for Advancement of Cytometry31. The file contains details
of antibodies, reagents, instrument settings, gating strategies and controls used for
flow cytometry experiments and is provided in the Supplementary Information of
this manuscript. PBMC were resuspended in cell staining buffer (Biolegend) in case
of proliferation assays or 1×PBS in case of ICS assays and incubated for 20 min
with near-infra-red live/dead or aqua fixable stain, respectively (Invitrogen,
Carlsbad, CA, USA). Cells from proliferation assays were incubated with
fluorochrome-conjugated primary human-specific antibodies for CD3, CD4 and
CD8 in cell staining buffer (Biolegend) containing serum for 30 min at 4 °C,
washed with cell staining buffer, fixed with 4% paraformaldehyde (PFA, Sigma)
and stored at 4 °C in the dark until data acquisition. Cells from ICS assays were
fixed with fixation/permeabilization solution (BD Biosciences) for 20 min at 4 °C,
washed with permeabilization buffer (BD Biosciences) followed by incubation with
fluorochrome-conjugated human-specific antibodies. After washing with permea-
bilization buffer, the samples were resuspended in 1×PBS and stored at 4 °C in the
dark until data acquisition. Data were acquired on an LSRII (BD Biosciences) or
MACSquant analyser 10 (Miltenyi) flow cytometer and analysis was performed
with FlowJo Version 10.7.1 (BD Biosciences). Specific gating strategies can be
found in the Supporting information.
Lactate measurements. Supernatants from the proliferation assay were analysed
using a published cellular lactate assay32. Briefly, colorimetric L-lactate assay kits
(Abcam, Cambridge, UK) were used as per the manufacturer’s instructions. A
standard concentration curve was defined, and the lactate concentration in each
day 4 supernatant from the proliferation assay was calculated using a 96-well plate
reader.
The lactate proliferation index was calculated on a per-well basis using the
following Eq. 1:
Proliferation %ð Þ ¼ 100 ´ TStim mean TDMSOð Þð Þ=TStim ð1Þ
where TStim is the concentration of lactate for a given well with either PHA or
SARS-CoV-2 peptides, and mean (TDMSO) is the average background lactate
production from negative control wells.
A significant proliferative response to a given peptide was greater than 0, as
determined by Eq. 2:
Significance ¼ mean TStimð Þ  3 ´ std TStimð Þ ð2Þ
where mean(TStim) is the mean % proliferative response of a specific participant to
a stimulus, and std(TStim) is the standard deviation of the participant to a given
stimulus.
Standardised ELISA for detection of spike-specific total IgG in plasma. Total
anti-SARS-CoV-2 spike antibodies were determined using an indirect ELISA29,
which is based on the Krammer assay33 using a standard curve derived from a pool
of SARS-COV-2 convalescent plasma samples on every plate. Standardised EUs
were determined from a single dilution of each sample against the standard curve
which was plotted using the 4-Parameter logistic model (Gen5 v3.09, BioTek). Each
assay plate consisted of samples and controls plated in triplicate, with ten standard
points in duplicate and four blank wells.
SARS-CoV-2 pseudotype micro-neutralisation assay. Frozen plasma samples
were thawed, heat-inactivated at 56 °C for 30 min, and assayed for neutralisation of
a lentivirus-based viral particle carrying a luciferase reporter and pseudotyped with
full-length SARS-CoV-2 spike (Accession No: YP_009724390.1)l34. Briefly, neu-
tralising antibody titres were determined by incubating serial two-fold plasma
dilutions with ~105 RLU pseudotyped virus for 2 h before the addition of 104
HEK293T cells transfected with full-length human ACE2 24 h prior. After 72 h
incubation at 37 °C, luciferase expression was quantified using BrightGlow (Pro-
mega Corp.), readouts were normalised, and −Log(IC50) determined via non-
linear regression using GraphPad Prism 8 (GraphPad Software).
Enzyme-linked immunosorbent assay for coronaviruses. 229E, NL63, HKU1
and OC43 spike antibody responses were measured using ELISAs. 229E, NL63,
HKU1 and OC43 spike antigens were bought from Sino Biological, China. Nunc-
Immuno 96-well plates (ThermoFischer Scientific, USA) were coated with 2.0 μg/
ml of antigen in PBS buffer and left overnight at 4 °C. Plates were washed with 3×
with 0.1% PBS–Tween (PBS/T), then blocked with casein in PBS for 1 h at room
temperature (RT). Serum or plasma was diluted in casein–PBS solution at 1:100
dilutions before being added to Nunc-Immuno 96-well plates in triplicate. Plates
were incubated for 2 h before being washed with 6× with PBS/T. Secondary anti-
body rabbit anti-human whole IgG conjugated to alkaline phosphatase (Sigma,
USA) was added at a dilution of 1:1000 in casein–PBS solution and incubated for
1 h at RT. After a final wash, plates were developed by adding 4-nitrophenyl
phosphate substrate in diethanolamine buffer (Pierce, Loughborough, UK), and
optical density OD was read at 405 nm using a BMG Labtech microplate reader. A
reference standard comprising of pooled cross-reactive serum and naive serum on
each plate served as positive and negative controls, respectively. The positive
reference standard was used on each plate to produce a standard curve from which
‘relative ELISA units’ were derived. Pooled HCoV highly reactive sera were used as
a standard for the HCoV spike ELISAs.
Alignment score analysis. SARS-CoV-2 sequence was downloaded from Gen-
Bank (accession number: NC_045512). All spike, M and NP protein sequences of
each of the HCoV species (OC43, HKU1, NL63 and 229E) were downloaded from
NCBI using a protein blast. For each protein of each species, all sequences were
aligned using MAFFT server (https://mafft.cbrc.jp/alignment/server/) and a con-
sensus sequence was constructed. The clinical sample with the least number of
mismatches relative to the consensus sequence was chosen as a representative
sequence for each protein of each HCoV species (see Supplementary Table 7, use
https://www.ncbi.nlm.nih.gov/protein/ for search). Matlab version R2018b was
used to align each SARS-CoV-2 peptide against HCoV proteins.
Needleman–Wunsch algorithm as implemented in Matlab (nwalign function) was
used to perform a semi-global alignment of each peptide and the alignment score
was recorded.
Statistical analyses. Statistical analysis was performed with IBM SPSS Statistics 25
and figures were made with GraphPad Prism 8. Chi-square was used to compare the
ratio difference between the two groups. After testing for normality using
Kolmogorov–Smirnov test, independent-samples t-test or Mann–Whitney U test
was employed to compare variables between two groups, and
Kruskal–Wallis–ANOVA with Dunn’s multiple comparisons test was performed to
compare variables between three or more groups with a non-parametric distribu-
tion. The correlation was performed via Spearman’s rank correlation coefficient. For
ICS cytokine expression analyses, data were prepared using PESTEL v2.0 for for-
matting and baseline subtraction, followed by the export of data to SPICE v6.0 for
analysis. Statistical significance was set at P < 0.05 and all tests were two-tailed.
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Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The SARS-CoV-2 sequence was accessed in the NCBI Gene database under accession
code NC_045512. All other data are present in the article and its Supplementary
Information files or from the corresponding author upon reasonable request. Source data
are provided with this paper.
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